{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,3]],"date-time":"2026-05-03T10:14:11Z","timestamp":1777803251565,"version":"3.51.4"},"reference-count":19,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T00:00:00Z","timestamp":1756857600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006188","name":"Einstein Foundation Berlin","doi-asserted-by":"publisher","award":["EVF\\u20102021\\u2013619\\u20132"],"award-info":[{"award-number":["EVF\\u20102021\\u2013619\\u20132"]}],"id":[{"id":"10.13039\/501100006188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006188","name":"Einstein Foundation Berlin","doi-asserted-by":"publisher","award":["EVF\\u20102021\\u2013619"],"award-info":[{"award-number":["EVF\\u20102021\\u2013619"]}],"id":[{"id":"10.13039\/501100006188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006188","name":"Einstein Foundation Berlin","doi-asserted-by":"publisher","award":["EVF-BUA-2022-694"],"award-info":[{"award-number":["EVF-BUA-2022-694"]}],"id":[{"id":"10.13039\/501100006188","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006188","name":"Einstein Foundation Berlin","doi-asserted-by":"publisher","award":["EJF\\u20102020\\u2013602"],"award-info":[{"award-number":["EJF\\u20102020\\u2013602"]}],"id":[{"id":"10.13039\/501100006188","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Autoimmunity"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jaut.2025.103476","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T11:02:56Z","timestamp":1757502176000},"page":"103476","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy\u2013A pilot study"],"prefix":"10.1016","volume":"157","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5306-7880","authenticated-orcid":false,"given":"Frauke","family":"Stascheit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Lehnerer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lea","family":"Gerischer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike","family":"Stein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Doksani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Meret","family":"Herdick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carla","family":"Dusemund","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Philipp","family":"Mergenthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Triller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan D.","family":"L\u00fcnemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hoffmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Meisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaut.2025.103476_bib1","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1038\/s41572-019-0079-y","article-title":"Myasthenia gravis","volume":"5","author":"Gilhus","year":"2019","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.jaut.2025.103476_bib2","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2100066","article-title":"Terminal complement inhibitor ravulizumab in generalized myasthenia gravis","volume":"1","author":"Vu","year":"2022","journal-title":"NEJM Evidence"},{"key":"10.1016\/j.jaut.2025.103476_bib3","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/S1474-4422(21)00159-9","article-title":"Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial","volume":"20","author":"Howard","year":"2021","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2025.103476_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1111\/j.1365-2990.2011.01178.x","article-title":"Loss of neurofilaments in the neuromuscular junction in a rat model of proximal axonopathy","volume":"38","author":"Soler-Mart\u00edn","year":"2012","journal-title":"Neuropathol. Appl. Neurobiol."},{"key":"10.1016\/j.jaut.2025.103476_bib5","doi-asserted-by":"crossref","DOI":"10.3389\/fneur.2022.1056322","article-title":"Serum neurofilament light chain in myasthenia gravis subgroups: an exploratory cohort and case\u2013control study","volume":"13","author":"Stascheit","year":"2023","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jaut.2025.103476_bib6","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.jaut.2013.12.011","article-title":"Myasthenia gravis: a comprehensive review of immune dysregulation and etiological mechanisms","volume":"52","author":"Berrih-Aknin","year":"2014","journal-title":"J. Autoimmun."},{"key":"10.1016\/j.jaut.2025.103476_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2023.103295","article-title":"Circulating Calprotectin (cCLP) in autoimmune diseases","volume":"22","author":"Manfredi","year":"2023","journal-title":"Autoimmun. Rev."},{"key":"10.1016\/j.jaut.2025.103476_bib8","doi-asserted-by":"crossref","DOI":"10.1016\/j.jtauto.2021.100111","article-title":"Calprotectin as potential novel biomarker in myasthenia gravis","volume":"4","author":"Stascheit","year":"2021","journal-title":"J Transl Autoimmun"},{"key":"10.1016\/j.jaut.2025.103476_bib9","article-title":"Serum neurofilament light chain in myasthenia gravis subgroups: an exploratory cohort and case-Control study","volume":"13","author":"Stascheit","year":"2022","journal-title":"Front. Neurol."},{"key":"10.1016\/j.jaut.2025.103476_bib10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","article-title":"Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study","volume":"16","author":"Howard","year":"2017","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jaut.2025.103476_bib11","series-title":"R: a Language and Environment for Statistical Computing","year":"2023"},{"key":"10.1016\/j.jaut.2025.103476_bib12","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1007\/s00415-025-13127-8","article-title":"Ravulizumab for generalized Myasthenia Gravis: a multicenter real-life experience","volume":"272","author":"Rossini","year":"2025","journal-title":"J. Neurol."},{"key":"10.1016\/j.jaut.2025.103476_bib13","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp-2024-334404","article-title":"C5 complement inhibition versus FcRn modulation in generalised myasthenia gravis","volume":"96","author":"Huntemann","year":"2025","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.jaut.2025.103476_bib14","doi-asserted-by":"crossref","first-page":"213","DOI":"10.3389\/fimmu.2020.00213","article-title":"Circulating miRNAs as potential biomarkers in Myasthenia Gravis: tools for personalized medicine","volume":"11","author":"Sabre","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jaut.2025.103476_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/ene.15730","article-title":"Complement activation profiles in Anti-AChR positive Myasthenia gravis","author":"Stascheit","year":"2023","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.jaut.2025.103476_bib16","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/s00401-024-02754-6","article-title":"Inter-alpha-trypsin inhibitor heavy chain H3 is a potential biomarker for disease activity in myasthenia gravis","volume":"147","author":"Schroeter","year":"2024","journal-title":"Acta Neuropathol."},{"key":"10.1016\/j.jaut.2025.103476_bib17","doi-asserted-by":"crossref","DOI":"10.3390\/brainsci12111439","article-title":"Metalloproteinases and tissue inhibitors in generalized Myasthenia gravis. A preliminary Study","volume":"12","author":"Di Stefano","year":"2022","journal-title":"Brain Sci."},{"key":"10.1016\/j.jaut.2025.103476_bib18","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-47559-x","article-title":"Residual serum fibrinogen as a universal biomarker for all serotypes of Myasthenia gravis","volume":"13","author":"Hussain","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.jaut.2025.103476_bib19","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22115755","article-title":"Fc-Receptor targeted therapies for the treatment of Myasthenia gravis","volume":"22","author":"Keller","year":"2021","journal-title":"Int. J. Mol. Sci."}],"container-title":["Journal of Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001210?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0896841125001210?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T05:25:53Z","timestamp":1772861153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0896841125001210"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":19,"alternative-id":["S0896841125001210"],"URL":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103476","relation":{},"ISSN":["0896-8411"],"issn-type":[{"value":"0896-8411","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Calprotectin and neurofilament serum levels correlate with treatment response in myasthenia gravis under intensified therapy\u2013A pilot study","name":"articletitle","label":"Article Title"},{"value":"Journal of Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaut.2025.103476","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"103476"}}